iHealthScreen Inc. has received a US patent for its iPredict glaucoma detection model, which leverages AI and color fundus imaging for early-stage glaucoma detection. This innovation, awarded the patent by USPTO on March 26, 2024, is designed for implementation in primary care settings. Previously, iHealthScreen was also awarded a patent for its age-related macular degeneration (AMD) screening model.

The iPredict model generates a fully automated detection report within 60 seconds after high-resolution retinal images are submitted, completing the entire process in less than 5 minutes. With an accuracy rate of 94.3%, this technology aims to prevent glaucoma progression and reduce blindness.

The glaucoma detection system categorizes results into referable (early to severe glaucoma) or nonreferable (no glaucoma), guiding patients to specialists if necessary. iHealthScreen's AI tools for diabetic retinopathy, AMD, and glaucoma are also CE certified and approved by MHRA/UK and TGA/Australia.

The company's automated reports recommend ophthalmologist visits for referable conditions and suggest follow-up screenings as per care standards, ensuring comprehensive eye health management in clinical settings.